Sanjay Kakkar Email & Phone Number

Milan, IT

US

Redwood City, California, US

• Tranquis (www.tranquis.com) is a clinical-stage biotech company discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases. Built.
• I have led the company since seed stage through a $30 million Series A financing, beginning with a virtual model to initially focus on establishing pre-clinical proof of concept with the lead compound (the sole asset a.

Redwood City, California, US

Pittsburgh, Pennsylvania, US

• Peptilogics (www.peptilogics.com) is a clinical-stage biotechnology company utilizing its proprietary computational drug design platform to rapidly and effectively develop novel peptide therapeutics, with an initial.
• Milestones achieved during my time: Completion of the Series A financing, initiation and completion of GLP tox studies, obtaining Qualified Infectious Disease Product (QIDP) designation from FDA, completion a.

• Armetheon, Inc., is a privately held, specialty pharmaceutical company developing and commercializing innovative medicines addressing major unmet needs in cardiovascular disease, initially in thrombosis and cardiac.

Santa Clara, California, US

• The Global Anticoagulant Registry in the FIELD (Garfield) is the largest, ongoing, prospective, multicentre, international registry of patients newly diagnosed with atrial fibrillation (AF). Garfield is an academic.

• Founder of the first personalized healthcare company developing technologies for the prevention and management of heart disease and other major non-communicable diseases (NCDs) for the emerging markets of the Indian.
• Designed and developed Jai Heart – the first genomics‐based risk estimation test for heart disease developed for the IOR. Jai Heart has been developed as a web-enabled solution and is in the process of being.
• Led a 2068 subject study clinically validating Jai Heart in India. The study demonstrated that Jai Heart is significantly better than the internationally accepted gold‐standard Framingham risk score at estimating the.

London, GB

• The Thrombosis Research Institutes consist of two research establishments in London and Bangalore and are dedicated to the study of thrombosis and related disorders.

• One of the founders of this emerging bio-pharmaceuticals company, linking private capital with the product discovery activities of a University of London research institute.
• Raised significant investment capital over several financing rounds for early-stage pre-clinical research, and clinical development of products originating from the company’s technologies.
• Built Trigen from its beginning as a virtual company based in an academic research institute to become a leading biotech company focused on cardiovascular diseases with a pipeline of competitive products at.
• Led Trigen through its spin-out from a research institute to become a free-standing company, built a highly regarded management team as well as a executing a significant merger with a German company in March 2005 to.
• Sold the UK subsidiary assets in 2008 and restructured the remaining operations to focus on the development of the assets of the German subsidiary.

• Anti-thrombotics, thrombolytics & anti-infectives

• Immunology & dermatology

• General and vascular surgery

• General medicine, cardiology and respiratory medicine

Master Of Public Health (Mph), Health Care Policy & Management

Master Of Science (Msc), Preventive Cardiology

Bachelor Of Medicine, Bachelor Of Surgery (Mbbs), Medicine

International Course On Antibiotics And Resistance (Icare), Antibiotics And Resistance